Europeans Forge Science Common Market

For Europe, a new and eagerly anticipated era begins in 1992. That’s the year in which the 12 nations of the European Economic Community (EEC) will abolish the last of the internal trade barriers that have made Europe an economic and technological hodge-podge ever since the EEC was created in 1957. Among other benefits, 1992 will harmonize the standards, specifications, and regulations that have governed virtually every European product or service—from new pharmaceuticals to life-

Written byGarrett Deyoung
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

For Europe, a new and eagerly anticipated era begins in 1992. That’s the year in which the 12 nations of the European Economic Community (EEC) will abolish the last of the internal trade barriers that have made Europe an economic and technological hodge-podge ever since the EEC was created in 1957.

Among other benefits, 1992 will harmonize the standards, specifications, and regulations that have governed virtually every European product or service—from new pharmaceuticals to life-insurance policies. For companies operating in more than one EEC nation, that crazy-quilt of standards has meant a costly multiplicity of product designs, packaging, and regulatory procedures. And so everyone from perfume makers to the big auto companies anticipates bigger profits when 1992 finally rolls around.

But corporate science is not waiting for 1992. In recent years researchers in European industry have jumped the gun, forging their own technological “common market.” Programs to promote intra-European joint ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies